Interim BNT162b2 LP.8.1-adapted COVID-19 Vaccine Effectiveness among Non-Immunocompromised Older Adults in California and Louisiana, August-December 2025
Zambrano, L. D.; Yu, T.; Mateus, J.; Zhao, X.; Andersen, K.; Valluri, S. R.; Karakuzu Ikizler, B.; Nepal, R. M.; MacNeil, A. J.; Volkman, H. R.
Show abstract
Evidence on vaccine effectiveness (VE) of 2025-26 COVID-19 vaccines is limited. We estimated VE of BNT162b2 LP.8.1-adapted vaccine among non-immunocompromised adults [≥]65 years through December 2025 using linked claims and immunization registry data from two U.S. states. VE against COVID-19-related ED/UC encounters was 48% (95% CI:19, 66).
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥65 years in the United States 95%
- 2024/25 end-of-season KP.2 vaccine effectiveness against COVID-19 hospitalization in older adults: a test-negative study in Quebec, Canada 95%
- 2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims 94%
Similar papers in this journal
- Health impact and cost of COVID-19 prophylaxis with monoclonal antibodies 92%
- Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial 92%
- Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical Trials 92%
Similar papers in this journal
- Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study 93%
- Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS) 92%
- Effectiveness of 13-valent pneumococcal conjugate vaccine against medically-attended lower respiratory tract infection and pneumonia among older adults 92%
Similar papers in this journal
- Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study 93%
- Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. Adults 93%
- Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalization among Finnish elderly and chronically ill – An interim analysis of a nationwide cohort study 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.